Compare McCormick & Company, Incorporated (MKC) vs TransMedics Group Inc (TMDX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
McCormick & Company, Incorporated vs TransMedics Group Inc — how do they compare? McCormick & Company, Incorporated trades at $44.84 (market cap $12.39B), while TransMedics Group Inc trades at $80.47 (market cap $2.74B). The key difference: McCormick & Company, Incorporated is far larger — about 4.5× TransMedics Group Inc's market cap, and McCormick & Company, Incorporated pays a 4.18% dividend while TransMedics Group Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold McCormick & Company, Incorporated for 67 Days and TransMedics Group Inc for 24 Days on average.
| MKC | TMDX | |
|---|---|---|
Market Cap | $12.39B | $2.74B |
Volume | 6,140,872 | 949,331 |
Sector | Consumer Staples | Health |
52-Week High | $71.65 | $150.42 |
52-Week Low | $44.14 | $61.99 |
Typical Hold Time | 67 Days | 24 Days |
Enterprise Value | $17.07B | $3.13B |
Dividend Yield | 4.18% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
MKC trades at $45.25, down 0.33% on the day, with a bearish technical signal but attractive valuation metrics including a P/E of 8.31. The company reported strong Q3 2026 earnings of $0.86 per share, beating estimates, driven by 17% sales growth and margin expansion. Recent dividend declaration of $0.48 per share provides income support. Revenue growth has been steady, reaching $6.84B in 2025 with net income of $789.4M.
The stock presents value opportunity with below-sector P/E ratio and consistent profitability (19.39% net margin), though technical indicators signal near-term weakness. Analyst consensus is mixed with 33% buy ratings but $53.50 price target suggests 18% upside. Key risks include integration challenges from acquisitions and consumer spending sensitivity.
TransMedics Group (TMDX) trades at $80.69, down 0.47% on the day, amid a bearish technical signal and mixed earnings performance. The company reported strong revenue growth to $605.49M in 2025 with a net income margin of 22.69%, but recent quarters have seen earnings misses. Analyst sentiment remains positive with a consensus price target of $99.75 and a 69% buy rating, though news flow includes investigations into fiduciary duties.
The outlook balances robust fundamentals against near-term headwinds. Upside potential exists from the high analyst target and strong profitability metrics like a 36.28% ROE, but risks include earnings volatility, margin pressure, and ongoing legal scrutiny. The stock's current valuation at a P/E of 20.47 offers a reasonable entry if execution improves.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About McCormick & Company, Incorporated
In its 130-year history, McCormick has grown to become the leading global manufacturer, marketer, and distributor of spices, herbs, extracts, seasonings, and other flavorings. Beyond end consumers, McCormick's customer base also includes top quick-service restaurants, retail grocery chains, and other packaged food and beverage manufacturers, with about 30% of sales generated beyond its home turf to include 150 other countries and territories. In addition to its namesake brand, the firm's portfolio includes Old Bay, Zatarain's, Thai Kitchen, Frank's RedHot, French's, and the recently acquired Cholula brand.
Read more on MKC →About TransMedics Group Inc
TransMedics is a pioneering medical technology company that is disrupting the organ transplant market with its Organ Care System (OCS™). By replacing traditional cold storage with portable warm perfusion, the OCS maintains donor organs in a near-physiologic state, allowing for continuous assessment and optimization. Through its National OCS Program (NOP™), TransMedics provides an end-to-end clinical and logistics solution, including a dedicated aviation fleet, to maximize the utilization of donor organs and improve patient outcomes.
Read more on TMDX →
